FDA Recall of Clonazepam due to Mislabeling

SOURCE www.foxnews.com
FDA recalls Clonazepam due to mislabeling, posing 'life-threatening' risks. Endo Inc. issues voluntary recall of 16 lots of Clonazepam Orally Disintegrating Tablets. Labeling error could lead to significant side effects including respiratory depression.

Key Points

  • FDA recall due to mislabeling of Clonazepam tablets by Endo Inc.
  • 16 lots of tablets mislabeled with incorrect strength and NDC
  • Mislabeling could lead to significant sedation, confusion, respiratory depression
  • No adverse effects reported as of Nov. 21

Pros

  • FDA taking proactive measure to protect public health
  • Clear communication about the recall to inform consumers

Cons

  • Mislabeling poses serious health risks to consumers
  • Potential for life-threatening side effects if mislabeled tablets are consumed